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effects of chronic amiodarone therapy on 
ventricular tachycardia induced by programmed 
ventricular stimGlation 
Several studieh have reported upon the inducibility of ventricular tachycardia (VT) with 
programmed ventricular stitiulation (PVS) during chronic amiodarone therapy; however, few 
&dies have systemaitfcaliy described and compared the morphoiogy, duration, atid cycle length 
of VT indtid by PVS before and after amkdarone. In this study, 26 patients with syymptomatic 
VT or ventrkuiar fibriliatkn were evaluated by PVS by means of one to three extr&timuii (ES) 
before treatment and after 2 inonths,of amkdsrone therapy. before amlodarone, Sustained 
unimorphic Vt was induced in 21 patients (group A) and symptomatic, nonsi&ained VT was 
induced In five patients (group B). After 65 f  6 days of cimiodarone (total dose 64.5 + 8.9 gm, 
mean f  S.D.), 15 of 21 patienis (71%) in group A had sustained VT, five patients (24%) had 
nonsustained VT, and one patlent had no VT IMiuced. Four at five patients (80%) in group B had 
sustained vt 8nd one patient had no VT induced. TT was Induced by the same or by fewsr 
number of ES in 79% of cases. When the morph&ogies of thi VT Induced before arid after 
amiodarone w6re compared, the morphology of TT lnducid after amiodar6ne was the same in 
oniy 8 of 24 patients (33%), unimorphic but different In 14 patients (56%), and polymorbhic in 
ths remaidng two patient& No correlation was found betweeti the serum conCe+ratkns of 
amiodarohe, desethylaakdarone, tetraioddthyronine, triiodothyronine, er reverse 
trikdQthyroinine, tid simiiaritles or differences in VT morphology, VT cycle length, or the relative 
number of ES required to ihduce VT after treatment with amiodarone. Although VT is often stilt 
inducible after 2 months of amiodarohe therapy, the VT induced Is different from the bas&tiine VT 
in the vast majo+lty of patients. (AM HEART J 1987;113:57.) 
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Several studies have reported upon the inducibility 
of ventricular tachycardia (VT) with programmed 
ventricular stimulation (PVS). However, there are 
very limited data which describe and compare the 
morphology, cycle length, and duration of ventricu- 
lar arrhythmias initiated by PVS before and after 
treatment with amiodarone. Furthermore, PVS has 
usually been limited to two ventricular extrastimuli 
in ahnost all patients evalulitsd in previous studies 
in which detailed descriptions of the induced VT 
have been report&d.” Be&use three ventricular 
extrastimuli may be required ti, induce VT in 
approximately 25% of patients who have a docu- 
me&d history of unimor@ic VT, the effects of 
chronic administration of amiodtione upon induced 
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VT in this subset of patients has been heretofore 
unkn~wn.~*~ The purpose of this sttiy, therefore, 
was to prospectively evaluate the effects of amioda- 
rone on VT induced by PVS ih patients with a 
documented his&y of symptomatic VT or ventricu- 
lar fibrillation (VF). 
METHODS 
Study patients. Twenty-six patients (21 men and 5 
women, age 62 + 7 ye&s; mean f standard deviation) 
with a history df one or more epiaodea of symptomatic VT 
or VF’ we& prospectively studied: They all met the 
following criteria: (1) symptotiatic VT or VF did not occur 
in association with acute myocardial infarction, electrolyte 
disturbance, metabolic abnormality, or proarrythmic drug 
effe (2) sustairied, unimorphic VT (duration of more 
than 30 seconds, or requiring termination due to hemody- 
namic collapse) or nonsustained unimorphic VT (duration 
of 6 beats or 530 seconds) teproducbig clinical symptoms 
could be initiated by PVS in the absence of antiarrhyth- 
mic therapy; (3) one Or more conventional ant&rhythmic 
agents failed to control spontaneous or induced VT or 
were not tolerated before treatment with amiodarone; and 
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Table I. Clinical features of 26 patients 
Patient 





1 72/M CAD 0.31 III VF CA 
2 58/M CAD 0.34 II VT-S 320 PdP 
3 58lM CAD 0.20 III VT-S 380 CHF 
4 70/F CAD 0.47 III VT-S 320 CA 
5 56/M CAD 0.49 II VT-S 420 SY 
6 59/M CAD 0.59 III VT-S 310 PSY 
7 59/M CAD II ND SY 
8 67lM CAD 0.28 III VT-S 260 Palp 
9 65/M CAD 0.45 III VF CA 
10 54/M CAD 0.33 III VT-NS 260 PdP 
11 69iM CAD 0.69 II VF CA 
12 56/M CAD 0.49 III VF CA 
13 67/F CAD 0.43 I VT-S 220 SY 
14 57/M CAD 0.43 III VF CA 
15 57/F CAD 0.37 III VF CA 
16 70/M CAD III VF CA 
17 71/M CAD 0.12 III VT-S 400 PSY 
18 74m HCM 0.62 II VT-S 320 SY 
19 64/F CAD 0.26 IV VF CA 
20 59/F CAD 0.35 II VF CA 
21 61/M CAD 0.34 III ND SY 
22 54/M CAD 0.29 II VT-S 300 Palp 
23 62/M CAD 0.37 III VT-S 300 PSY 
24 59/M CAD 0.23 III VT-S 320 CA 
25 64/M CAD 0.26 III VF CA 
26 48/M CAD 0.48 II VT-S 300 SY 
Abbreviations: CA = cardiac arrest; CAD = coronary artery disease; CHF = congestive heart failure: CL = cycle length; EF = ejection fraction; F = female; 
I-KM = hypertrophic cardiomyopathy; M = male; ND = not documented, NS = nonsustained; NYHA = New York Heart Association; Palp = palpitations; 
PSy = presyncope; S = sustained; Sy = syncope; VF = ventricular fibrillation; VT = ventricular tachycardia. 
(4) amiodarone was administered as the sole antiarrhyth- 
mic agent. 
The clinical features of our study patients are summa- 
rixed in Table I. Twenty-five patients had coronary artery 
disease, 24 of whom had a clinical history of a myocardial 
infarction a minimum of 6 weeks before the first sponta- 
neous occurmnce of symptomatic VT or VF. One patient 
had symmetric hypertrophic cardiomyopathy. The mean 
ejection fraction, determined in 24 of 26 patients (92% ), 
was 0.35 + 0.12. Before treatment with smiodarone, 12 
patients had a history of cardiac arrest during which VT 
or ventricular fibrillation was documented. Seven patients 
experienced presyncope or syncope during a documented 
occurrence of VT, two additional patients experienced 
ayncope after a prodrome that strongly suggested occur- 
rence of a tachyarrhythmii. Five patienta had palpitations 
or symptoms of congestive heart failure during docu- 
mented episodes of nonsustained or sustained VT. Five 
petienta had unimorphic VT documented by a la-lead 
ECG, and 19 patients had unimorphic VT or VF docu- 
mented during single-channel ECG telemetry monitor- 
ing. 
After amiodarane therapy, VT was considered inducible 
if it had a duration of more than five beats. SusW VT 
was defined as having a duration of more than 30 seconds 
or requiring termination due to hemodynamic collapse. 
Nonsustained VT was defined as having a duration of 
more than five beats but less than 31 seconds. 
Eiectropbysklogy study protocol. After the patients 
gave informed consent, they underwent an electrophysio- 
logic study in the fasting, unsedated state, at least 4 
half-lives after discontinuation of antiarrhythmic drugs. 
Digitalis, if required for heart failure, or beta-adrenergic 
blocking agents and calcium channel antagonists, if pre- 
scribed for hypertension or angina pectoris, were contin- 
ued during the initial electrophysiology study, for the 
entire period of treatment with amiodarone, and during 
subsequent electropharmacologic testing of amiodarone. 
Two quadripolar electrode catheters were inserted percu- 
taneously into a femoral vein and were positioned in the 
appropriate cardiac chamber. After the completion of 
atrial stimulation, whenever clinically indicated, the elec- 
trode cath&rs were positioned against the apex and 
outflow tract of the right ventricle. ECG leads V1, I, and 
III, and intracardiac right ventricular electrograms were 
displayed on an oscilloscope and were recorded at a paper 
speed of 25 to 100 mmfsec with an Electronics for 
Medicine VB 16 recorder (Electronics for Medicine/ 
BoneywQll Inc., Pleasantville, N.Y.). Pacing was perform- 
ed with a programmable stimulator (Bloom Associates, 
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Table II. Results of programmed ventricular stimulation in patients having ventricular tachycardia with the same 
morphology before and after amiodarone 
Baseline Amiodarone 
Patient CL DCL Method of CL DCL Method of 
no. Morphology (m-see) Site (msec) ES termination Morphology (msec) Site (msec) ES termination 
1 IND 220 RVOT 500 3 cvw IND 230 RVOT 400 3 W2) 
2 LBB-S 260 RVA 400 3 OP(4) LBB-S 300 RVA 400 2 OP(U 
RBB-S 240 RVOT 400 3 opt51 
3 RBB-I 380 RVA 500 2 OP(7) RBB-I 520 RVA 500 1 W6) 
4 LBB-S 280 RVA 600 3 owl) LBB-S 460 RVA 400 2 wu 
5 RBB-S 420 RVA 600 1 Sp RBB-S (NS) 420 RVOT 400 3 Sp 
6 RBB-I 350 RVA 400 2 OP(3) RBB-I 600 RVOT 400 2 Sp 
LBB-S 360 RVA 400 2 OPW LBB-S 400 RVA 400 3 Sp 
7 RBB-S (NS) 250 RVOT 400 2 Sp RBB-S 280 RVA 600 3 cvw 
8 RBB-I 280 RVA 500 2 OPU) RBB-I 400 RVA 600 2 Wl) 
LBB-S 280 RVA 500 2 OPW IND-I 400 RVA 600 2 Wl) 
Abbreviations and symbols: CL = cycle length; CV = cardioversion; DCL = drive cycle length; ES = extrastimuli; I = inferior axis; IND = indeterminate 
but unimorphic; LBB = left bundle branch; No. = number; NS = nonsustained; OP = overdrive pacing; RBB * right bundle branch; RVA = right 
ventricular apex; RVOT = right ventricular outflow tract; S = superior axis; V = ventricular; Sp = spontaneous; numbers in parentheses = number of 
attempta required to successfully terminate induced ventricular tachycardia. 
Narberth, Pa.). The stimuli were twice diastolic threshold against the apex and outflow tract of the right ventricle. 
and had a pulse width of 2 msec. PVS was repeated with the protocol described above. 
Our protocol for programmed ventricular stimulation 
has been described previously.6 With the use of a drive 
train of six to eight stimuli at a cycle length of 666 or 566 
msec, programmed stimulation was performed at the right 
ventricular apex with a single extrastimulus (S,) until 
ventricular refractoriness was reached, then with double 
extrastimuli (,I$&). This was repeated with a drive cycle 
length of 460 msec. Due to competition during ventricular 
pacing, different drive cycle lengths were required in six 
patients. Single and double extrastimuli were then intro- 
duced at the right ventricular outflow tract by means of 
the same two drive cycle lengths that were used at the 
right ventricular apex. Programmed stimulation was then 
performed with the use of the same two drive cycle lengths 
at the right ventricular apex (RVA) with triple extrastim- 
uli (S,S$,), with Sz and S, initially positioned 30 msec 
beyond their respective points of ventricular refractori- 
ness, and S, positioned 360 msec beyond S,. Diastole was 
scanned with S&S, in 10 msec steps. Triple extrastimuli 
were then introduced at the right ventricular outflow tract 
(RVOT). The end point of the stimulation protocol was 
either one induction of VT requiring direct-current coun- 
tershock for termination, or two or more inductions of 
sustained VT not requiring direct-current countershock. 
Amiodarone was generally well tolerated by the majori- 
ty of patients in this study, although several patients 
experienced hand tremor or mild ataxia. No patient 
required discontinuation of amiodarone because of 
adverse reaction or hospitalization for recurrent arrhyth- 
mia during the treatment period. The mean total dose at 
the time of the second electrophysiologic study was 46.5 -t 
8.9 gm. 
Quantttatlon of amiodarone in serum. Serum concen- 
trations of amiodarone and its desethyl metabolite, dese- 
thylamiodarone, were determined by high-pressure liquid 
chromatography with the method of Flanagan et aL7 
RESULTS 
The resulta of PVS before and after amiodarone 
are summarked in Tables II and III. 
Amlodarone therapy and follow-up electrophysiology 
study. Amiodarone was administered in oral doses of 1200 
mg daily for 7 days, 606 mg daily for 28 days, 600 mg daily 
for 28 days, and then 460 mg daily thereafter. Patients 
were discharged from the hospital after 8 to 12 days of 
therapy, and were readmitted after 65 f 8 days of treat- 
ment for electropharmacologic testing of amiodarone. 
Two quadripoku electroda catheters were reinserted per- 
cutaneously into a femoral vein and were repositioned 
Morphology and cycle length of induced VT before 
amiodarone. Thirty-two VTs with a uniform mor- 
phology were initiated in 26 patients before treat- 
ment with amiodarone. Unimorphic, sustained VT 
was initiated in 21 patienta and unimorphic, nonaus- 
tained VT was initiated in five patients. Five 
patients had unimorphic VT with more than one 
morphology initiated during the baseline electro- 
physiologic study. The mean cycle length of VT 
before amiodarone was 264 k 74 msec. 
Comparison of morphology and cycle length of 
induced VT with spontaneous VT before emlodarone. In 
four of five patients whose spontaneous VT was 
documented with a la-lead ECG, the VT initiated 
by programmed VT before amiodarone had the 
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Table III. Results of programmed ventricular stimulation in patients having ventricular tachycardia (VT) with a 
different morphology or no inducible VT after amiodarone 
Baseline Amiodarone 
Patient CL DCL Method of CL DCL Method of 
















LBB-S 290 RVOT 400 
RBB-S 200 RVOT 400 
LBB-S (NS) 200 RVA 450 
RBB-S 480 RVA 500 
RBB-I (NS) 205 RVA 400 
RBB-S (NS) 240 RVOT 600 
LBB-S 360 RVA 550 
RBB-S 360 RVA 600 
LBB-S 340 RVA 600 
LBB-I 280 RVA 550 
RBB-I (NS) 200 RVOT 375 
RBB-S (NS) 200 RVOT 315 
LBB-S 240 RVA 600 
IND 200 RVA 600 
RBB-S 315 RVA 600 
RBB-I 280 RVA 600 
LBB-S 209 RVA 600 
RRB-S 320 RVA 600 
24 RBB-S 320 RVA 600 
25 RBB-S 250 RVA 400 











































RBB-S (NS) 320 RVA 400 3 SP 
PM 300 RVA 600 2 CV(1) 
PM (NS) 200 RVA 600 3 SP 
LBB-I 480 RVOT 600 2 OP(1) 
RBB-S 250 RVA 550 2 CV(1) 
LBB-S 280 RVA 600 2 CV(1) 
RBB-S 360 RVA 400 3 OP(1) 
LBB-S (NS) 360 RVA 600 3 SP 
LBB-I 440 RVA 490 2 OP(6)-CV(1) 
RBB-I (NS) 360 RVA 400 3 SP 
LBB-S 290 RVOT 375 3 OP(17)-CV(1) 
RBB-I 320 RVA 600 2 OP(3) 
RBB-I 280 RVA 600 2 OP(10) 
LBB-I 470 RVA 500 2 OP(1) 
RBB-S* 280 RVA 600 2 OP(2) 
LBB-S 360 RVA 600 2 OP(1) 
RBB-S* 360 RVA 600 3 SP 
LBB-S 320 RVA 600 3 OP(1) 
Abbreviations and symbols: PM * polymorphic; * = different QR.6 configuration and axis change of 30 to 40 degrees when compared to ventricular 
tachycardia induced before treatment-not due to increased duration intraventricular conduction alone. The remaining abbreviations and symbols are as in 
Table I. 
same configuration. In the remaining patient, the 
induced VT before amiodarone was different when 
compared to spontaneous VT that had been docu- 
mented by a 12-lead ECG during treatment with 
quinidine. 
Morphology and cycle length of induced VT after 
amlodarone. After 65 + 8 days of treatment with 
amiodarone, 28 W’s were induced in 24 of 26 
patients (92%). VT was unimorphic and suetained 
in 18 patienta (75%), unimorphic and nonsu&ained 
in four patients (17 % ), polymorphic and sustained 
in one patient (4%), and polymorphic and nonsus- 
tained in one patient (4 % ). In two patients VT could 
not be initiated by PVS after treatment with amio- 
darone. The mean cycle length of VT increased from 
282 + 75 msec before amiodarone to 365 + 91 meet 
after amiodarone (p < 0.01). 
Comparison of VT duration and morpholagy before 
and after amlodarone. Of the 21 patients who had 
sustained, unimorphic VT before treatment with 
amiodarone, 15 patients (71%) had sustained VT, 
five patients (24%) had nonsust&& VT, and one 
patient (5%) had no VT initiated after amiodarone. 
Of the five patients who had nonsustained, uni- 
morphic VT induced before amiodarone, four 
patients (80% ) had sustained VT and one patient 
had no VT after amiodarone. 
The morphology of VT induced after treatment 
with amiodarone was the same as the baseline VT in 
only 8 of the 24 patients (33 % ) in whom VT WBB 
induced after amiodarone, and different in the other 
16 patienta (67% ). Three of the five patients who 
had unimorphic VT with more than one morphology 
initiated by PVS before amiodarone had VT with 
more than one morphology induced after amioda- 
rone. Three of the remaining 21 patients (14%) who 
had unimorphic VT induced with only one morphol- 
ogy before amiodarone had unimorphic VT induced 
with more than one morphology initiated after 
amiodarone. 
Comparison of cycle lengths of Induced VT before 
and after amtodarone. In patients in whom the config- 
uration of the induced VT remained the same before 
and after amiodarone, the mean cycle length 
in-d from 311 it 68 to 401 -+ 118 msec 
(p < 0.02). In patients in whom the co&guratiOn of 
the induced VT differed before and after amioda- 
rone, the llnsan cycle length increased from 271 & 79 
to 346 It 74 meet (p < 0.01). 
Comparloon of ventricular effective refractory perl- 
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ods before and after amiodarone. The ventricular 
effective refractory period was compared before and 
after amiodarone at the same right ventricular site 
and at the same driven cycle length in 18 of 26 
patients. The ventricular effective refractory period 
increased after amiodarone from 280 & 29 to 364 f 
26 msec at a driven cycle length of 600 msec 
(p < 0.02), and from 248 -+ 29 to 293 f 32 msec at a 
driven cycle length of 400 msec (p < 0.01). No 
correlation was found between changes in ventricu- 
lar effective refractory period and the inducibility or 
noninducibility of VT, the method of VT induction, 
changes in VT morphology, or duration of induced 
VT after amiodarone. 
Comparison of method of induction of VT before and 
after amiodarone. When compared to the results of 
PVs before amiodarone, the same number of extra- 
stimuli induced 17 of the 28 VTa (61%) observed 
after amiodarone. When the same number of extra- 
stimuli induced VT after amiodarone, the morphol- 
ogy of 4 of the 17 VTs (24%) observed was the same 
and 13 (76%) were different. A fewer number of 
extrastimuli were required to induce 5 of the 28 VTs 
(18 % ) observed after amiodarone. The morphology 
of three of these five VTs (60 % ) was the same and in 
two (40%) it was different. A greater number of 
extrastimuli were required to induce 6 of the 28 VI’s 
(21% ) observed after amiodarone. The morphology 
of three of these six VTs (50%) was the same and in 
three (50%) it was different. 
Comparison of site of VT induction before and after 
amiodarone. VT was initiated after amiodarone at 
the same right ventricular site in 18 of 24 patients 
(75 % ). The morphology of the VT induced after 
amiodarone at this site was the same as the baseline 
VT in six patients (33%) and different in 12 patients 
(67%). VT was initiated after amiodarone at a 
different site in 6 of 24 patients (25% ). The mor- 
phology of the VT induced after amiodarone at this 
new site was the same as the baseline VT in three 
patients (50%) and different in three patients 
(50% 1. 
Correlation of induction of VT with serum amioda- 
rone, desethyiamiodarone, and thyroid hormone con- 
centrations. The following concentrations were 
determined in all patients from serum at the time of 
repeat PVS after chronic treatment with amioda- 
rone:amiodarone ranged from 1.1 to 4.5 (mearn2.3 -+ 
0.7 mg/L; desethylamiodarone ranged from 0.5 to 2.2 
(meam1.3 + 0.4) mg/L; tetraiodothyronine (Td) 
ranged from 4.3 to 15.3 (meam9.6 + 2.7) &dl; 
triiodothyronine (T3) ranged from 90 to 119 
(mean:102 + 7) ng/dl; reverse triiodothyronine (rT,) 
ranged from 314 to 1813 (mean: 663 + 340) ng/dl. 
No correlation was found between serum amioda- 
rone, desthylamiodarone, T,, T3, or rT, concentra- 
tions and similarities or differences in VT morphol- 
ogy, VT cycle length, or the relative number of 
ventricular extrastimuli required to induce VT after 
treatment with amiodarone relative to the number 
of ventricular extrastimuli required before treat- 
ment. 
Comparison of method of termination of induced VT 
before and after amiodarone. Before treatment with 
amiodarone, VT induced by PVS was terminated by 
a single synchronized 100 J transthoracic shock in 
four patients and by overdrive pacing in 14 patients. 
VT terminated spontaneously in six patients. After 
amiodarone, VT induced by PVS was terminated by 
a single, synchronized 100 J transthoracic shock in 
six patients, by two sequential 100 J transthoracic 
shocks in one patient, and by overdrive pacing in 11 
patients. VT terminated spontaneously in six 
patients. Of the four patients who had induced VT 
terminated by cardioversion before amiodarone, two 
patients had induced VT terminated by cardiover- 
sion after amiodarone. One of these two patients 
required more than a single, synchronized 100 J 
transthoracic shock to terminate induced VT. The 
remaining two patients had induced VT terminated 
by overdrive pacing. 
Of the 14 patients who had induced VT terminat- 
ed by overdrive pacing before amiodarone, nine 
patients had induced VT terminated by using the 
same or fewer attempts with overdrive pacing after 
amiodarone (Tables II and III). One other patient, 
whose induced VT was terminated on the first 
attempt with overdrive pacing before amiodarone, 
had induced VT after amiodarone that required 
termination by cardioversion after six unsuccessful 
attempts with overdrive pacing. The remaining four 
patients had VT terminate spontaneously after 
amiodarone. Of the six patients who had induced 
VT terminate spontaneously before amiodarone, 
two patients had induced VT terminate spontane- 
ously, three patients had induced VT that was 
terminated by cardioversion, and one patient had 
induced VT terminated by cardioversion after 17 
unsuccessful attempts with overdrive pacing after 
amiodarone. 
DISCUSSION 
Antiarrhythmic effects of amiodarone. After 2 
months of oral therapy with amiodarone, sustained 
unimorphic VT was still inducible by PVS in 84 % of 
patients with a documented history of symptomatic 
VT or VT and inducible, unimorphic VT before 
treatment. However, in only eight patients (33%) 
was the configuration of the VT induced after 
amiodarone the same as the configuration of the 
62 DiCarto et al. 
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baseline VT. In the majority of patients, amiodarone 
suppressed the original morphology of VT induced 
before treatment even though VT remained induc- 
ible after treatment with the same or a fewer 
number of ventricular extrastimuli. 
Such changes in VT morphology have not been a 
consistent observation during chronic amiodarone 
therapy in other studies. Veltri et al.4 reported that 
the morphology of induced VT remained similar in 
each of 12 patients evaluated before and after 1.5 to 
15 months of amiodarone, whereas otherG3 have 
reported morphologically new VT being induced in 
41% to 72% of patients after 0.75 to 18 months of 
amiodarone therapy. In these studies, however, PVS 
was usually limited to a maximum of two ventricular 
extrastimuli, or the protocol for inducing VT includ- 
ed ventricular burst pacing or introduction of ven- 
tricular stimuli during sinus rhythm or atrial pacing. 
Therefore, the apparent differences observed in the 
effect of amiodarone upon the morphology of 
induced VT could have been due to differences in 
the patient population, the programmed ventricular 
stimulation protocol, or the interval of time between 
initiation of treatment with amiodarone and evalua- 
tion of its effects in the electrophysiology laborato- 
rY. 
In two patients polymorphic VT was initiated 
after amiodarone. The significance of this finding is 
not clear. Previous studies6*6~6,9 have demonstrated 
this induced arrhythmia to be a nonspecific response 
to programmed stimulation in patients with and 
without documented occurrences of unimorphic VT 
before treatment. However, further studies may be 
necessary in order to address the clinical signifi- 
cance of polymorphic VT that is induced only after 
initiation of antiarrhythmic therapy. 
Proarrhythmlc effects of amiodarone. Several obser- 
vations in this study suggested that amiodarone may 
have potential proarrhythmic effects. Although 
amiodarone suppressed by least one morphology of 
induced VT in three of the five patients who had 
more than one morphology induced before treat- 
ment, three additional patients who had only one 
morphology of VT induced before amiodarone had 
more than one morphology of VT induced after 
amiodarone. This observation differs from that of 
Reddy et al.,3 who reported suppression of all VTs in 
each of four patients who had two types of VT 
before amiodarone and no increase in the number of 
morphologies induced in any other patient after 
amiodarone. 
In 10 patients, VT with a new morphology was 
initiated at the same right ventricular site with the 
same or fewer number of ventricular extrastimuli 
after amiodarone. It is possible that this morpholog- 
ically new VT could represent a proarrhythmic 
effect of amiodarone, since a similar morphology was 
not induced before amiodarone despite stimulation 
at the same ventricular site with the same number of 
extrastimuli and similar coupling intervals. Four of 
five patients (80%) who had nonsustained VT 
induced before amiodarone had sustained VT 
induced by PVS after amiodarone. This latter obser- 
vation is compatible with previous studies10-13 that 
have demonstrated a similar proarrhythmic effect 
after administration of amiodarone as well as other 
antiarrhythmic agents. 
Correlation of results of PVS with serum amiodarone, 
desethylamtodarone, and thyroid hormone concentra- 
tions. No correlation was found between the serum 
concentrations of amiodarone or its desethyl metab- 
elite and the results of PVS. Although it has been 
suggested by some investigators that amiodarone 
might exert its salutary effect on the myocardium 
because of its effects upon thyroid hormone metab- 
olism,‘” Reddy et al3 observed no correlation 
between serum rT, concentrations and inducibility 
of VT during chronic amiodarone therapy. The 
results of this study extend these observations to 
include no correlation between serum concentra- 
tions of T,, T3, or rT3 and similarities or differences 
in VT morphology, VT cycle length, or the relative 
number of ventricular extrastimuli required to ini- 
tiate VT after treatment with amiodarone. It would 
appear unlikely, therefore, that amiodarone exerts 
any of its beneficial effects upon induced ventricular 
arrhythmias due to changes in circulating thyroid 
hormone concentrations. 
Comparison wlth previous studies. The protocol for 
PVS in this study included a maximum of three 
extrastimuli in all patients studied. Three ventricu- 
lar extrastimuli were required to induce 12 of 31 VTs 
(40% 1 before amiodarone and 13 of 29 VTs (45%) 
after amiodarone after a minimum of two extrastim- 
uli failed to induce VT at two right ventricular sites 
with the use of two ventricular drive rates. This 
requirement of three extrastimuli to induce uni- 
morphic VT before amiodarone is compatible with 
previous work,Sa I5 that has demonstrated the need to 
use three extrastimuli to initiate VT in approxi- 
mately 26% of patients with a documented history 
of uniform VT. In earlier studies’“’ in which a 
detailed description of the induced VT has been 
reported, PVS has usually been limited to two 
ventricular extrastimuli in almost all patients. 
Therefore, the effects of chronic administration of 
amiodarone upon induced VT in thii subset of 
patients have been heretofore unknown. 
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Because of the long elimination half-life of amio- 
darone, PVS was delayed for 2 months after the 
initiation of treatment with amiodarone; However, a 
strict comparison between the results of PVS in this 
study and previous studies is difhcult. Previous 
workI has suggested that the maximal amiodarone 
effect upon ventricular effective and functional 
refractory periods and suppression of inducible, 
sustained VT occurs after 6 to 8 weeks or oral 
therapy. In many studies reported to date,” 17-22 PVS 
has been performed after a .shorter period of amio- 
darone therapy, long before the elimination half-life 
of amiodarone and its maximal potential electro- 
physiologic and antiarrhythmic effects have been 
reached. In other studies3* ‘* 23* U where PVS has been 
performed in all patients at least 6 weeks after 
initiation of amiodarone therapy, the interval 
between the baseline and follow-up electrophysio- 
logic studies in some reports has been as long as 15 
tc 18 months. After such long time intervals, the 
results of PVS could reflect a change in the sub- 
strate responsible for VT due to progression of 
underlying heart disease. 
Difficulty in terminating recurrent ventricular 
arrhythmias during amiodarone therapy has been 
reported. Fogoros et al.‘O observed VT/VF become 
refractory to cardioversion in 5 of 77 patients (6 % ) 
treated with amiodarone. In the present study, 
greater difficulty was encountered in terminating 
induced VT during amiodarone therapy in one of 
two patients whose induced VT had been terminat- 
ed successfully by a single synchronized transtho- 
racic shock and in 1 of 10 patients whose induced 
VT had been terminated successfully by overdrive 
pacing before amiodarone. Four additional patients 
whose induced VT terminated spontaneously before 
amiodarone had induced VT that required termina- 
tion by cardioversion after amiodarone. Two of 
these four patients had VT induced by the same 
number of ventricular extrastimuli and two patients 
had VT induced by a fewer number of extrastimuli 
after amiodarone. Therefore, the requirement of 
transthoracic cardioversion for these four patients 
cannot be explained simply on the basis of having 
exposed more malignant forms of VT due to more 
aggressive stimulation methods after administration 
of amiodarone. 
Limitations. One limitation of this study is that 
documentation of clinical ventricular arrhythmias 
with a 124ead ECG was possible in only a minority 
of patients studied. It cannot be stated with absolute 
certainty, therefore, that the morphology of VT 
induced by PVS before amiodarone treatment rep- 
resented the same tachycardia that occurred clini- 
Amiodarone and ventricular tachycardia 63 
tally in all cases. Second, endocardial mapping of 
VT was not performed during PVS. It could not 
determined, therefore, whether amiodarone sup- 
pressed the original VT by suppressing the original 
VT focus or by changing the exit point of the 
original VT focus. Third, due to technical limita- 
tions, such as competition from sinus rhythm or 
ventricular premature depolarizations during ven- 
tricular pacing, the ventricular drive rates used 
during PVS before and after amiodarone was not 
uniform in all patients. We cannot exclude the 
possibility that this may have affected the number 
of extrastimuli required to achieve the critical cou- 
pling interval necessary for induction of VT in some 
patients 
In conclusion, this study has demonstrated that 
although VT is often still inducible after 2 months of 
amiodarone therapy, the VT induced is different 
from the baseline VT in the vast majority of 
patients. Long-term follow-up will be necessary to 
assess whether this might affect the predictive accu- 
racy of electropharmacologic testing with amioda- 
rone. 
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